1
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Condition(s):Acute GVHDLast Updated:March 1, 2021Recruiting
Tacrolimus: 1540 Clinical Trials, Page 1 of 154
Hide Studies Not Open or Pending
2
Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
Condition(s):Liver Transplantation; Immunosuppression; Neurotoxicity; Tremor; TacrolimusLast Updated:October 22, 2021Not yet recruiting
3
Tacrolimus Treatment for Refractory Autoimmune Cytopenia
Condition(s):Autoimmune Hemolytic Anemia; Pure Red Cell Aplasia; Evans SyndromeLast Updated:December 3, 2019Unknown status
4
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
Condition(s):Transplant;Failure,KidneyLast Updated:March 19, 2021Recruiting
5
OPTImization of the Dose of tacroliMUS by Bayesian Prediction
Condition(s):KIDNEY TRANSPLANTATIONLast Updated:January 8, 2021Completed
6
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
Condition(s):Heart Transplant Failure and RejectionLast Updated:April 22, 2021Recruiting
7
Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells
Condition(s):HemochromatosisLast Updated:September 4, 2018Completed
8
Tacrolimus Treatment for Refractory PRCA
Condition(s):Pure Red Cell AplasiaLast Updated:May 30, 2018Unknown status
9
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
Condition(s):Kidney Transplantation; Pancreas Transplantation; DiabetesLast Updated:August 9, 2021Recruiting
10
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
Condition(s):Hereditary Hemorrhagic Telangiectasia; Epistaxis NosebleedLast Updated:July 12, 2021Recruiting